Defactinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications
RAF/MEK Clamp Inhibition with Avutometinib and Cetuximab in RAF1 S257L-Mutated, Anti-EGFR-Refractory Metastatic Colorectal Cancer in Gaucher's disease.
Journal: The oncologist
Published: July 08, 2026
Corrigendum to 'Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer' [International Journal of Gynecological Cancer Volume 36 Issue 5 (2026) 104635].
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 12, 2026
Scaffold hopping-directed design and discovery of N1-substituted aminopyrimidine-indole derivatives as FAK inhibitors with anti-pancreatic cancer activity.
Journal: Bioorganic & medicinal chemistry
Published: June 01, 2026
An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Journal: Expert review of anticancer therapy
Published: April 30, 2026
Simultaneous Estimation of Avutometinib and Defactinib in Rat Plasma by Using LC-MS/MS and Its Application to Pharmacokinetic Studies.
Journal: Biomedical chromatography : BMC
Published: April 29, 2026
Vitronectin enrichment in prostate cancer liver metastases promotes adhesion and survival.
Journal: Cancer research communications
Published: April 24, 2026
Electrospun Hyaluronic Acid/Polyvinyl Alcohol Nanofibers Encapsulating Defactinib as Bioactive Dressings for Burn Wound Therapy.
Journal: ACS applied bio materials
Published: March 12, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.
Journal: Pharmacological research
Published: January 20, 2026
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review.
Journal: British journal of pharmacology
Published: January 16, 2026
Last Updated: 09/26/2026